NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia · Delayed Price · Currency is AUD 0.0710
-0.0040 (-5.33%)
At close: Mar 27, 2026
ASX:NSB Revenue
NeuroScientific Biopharmaceuticals had revenue of 317.91K AUD in the half year ending December 31, 2025. This brings the company's revenue in the last twelve months to 317.91K, down -85.63% year-over-year.
Revenue (ttm)
317.91K
Revenue Growth
-85.63%
P/S Ratio
74.28
Revenue / Employee
n/a
Employees
n/a
Market Cap
23.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | 2.21M | -2.74M | -55.34% |
| Jun 30, 2023 | 4.95M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | 958.77K | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 61.40M |
| Neurotech International | 7.07M |
| Prescient Therapeutics | 4.27M |
| Imugene | 3.94M |
| Noxopharm | 3.40M |
| Proteomics International Laboratories | 3.21M |
| Entropy Neurodynamics | 1.58M |
| Avecho Biotechnology | 1.24M |